Image pharmaphorum Editor R&D Does the answer to advancing rare disease treatment lie in r... What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population. R&D Why VCs fell in love with pharma R&D in 2021 For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things. R&D Emerging technologies that are changing the way healthcare i... Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses. R&D Medical Informatics in Rare Disease – the bridge between two... Rare diseases bring with them a multitude of challenges for those affected, their relatives and care providers. Load more results
R&D Does the answer to advancing rare disease treatment lie in r... What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population.
R&D Why VCs fell in love with pharma R&D in 2021 For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
R&D Emerging technologies that are changing the way healthcare i... Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses.
R&D Medical Informatics in Rare Disease – the bridge between two... Rare diseases bring with them a multitude of challenges for those affected, their relatives and care providers.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
